GW Pharmaceuticals Plc (GWPH)

95.00
2.04 2.10
NASDAQ : Health Technology
Prev Close 97.04
Open 97.83
Day Low/High 94.44 / 97.88
52 Wk Low/High 67.98 / 141.98
Volume 259.89K
Avg Volume 342.90K
Exchange NASDAQ
Shares Outstanding 31.08M
Market Cap 4.03B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GW Pharmaceuticals Has Been Basing but Needs More Development

GW Pharmaceuticals Has Been Basing but Needs More Development

Let's check out the charts and indicators of this drug maker.

Bearish Bets: 2 Fragile-Looking Stocks You Should Consider Shorting This Week

Bearish Bets: 2 Fragile-Looking Stocks You Should Consider Shorting This Week

These names are displaying both technical and quantitative deterioration.

Bank Stress Tests, FDA Drug Approvals, Covid-19

Pre-market futures are now pointing to a slightly down open. Bank stress test have the financial sector under pressure as the Financial Select Sector SPDR ETF is down over 1% close to the opening bell. Zogenix should have a good day. The FDA approve...

Cannabis Companies Eyeing How Plant Could Help Autism Symptoms

Cannabis Companies Eyeing How Plant Could Help Autism Symptoms

After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.

GW Pharmaceuticals Looks Like It Is Ending Its Downtrend

GW Pharmaceuticals Looks Like It Is Ending Its Downtrend

Time to go long?

Picked Up Some GW Pharma

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

The Market Is Still in Reset Mode, but Indices Are Holding Up

The Market Is Still in Reset Mode, but Indices Are Holding Up

Many stocks need rest and small-cap earnings season is rocky, but that doesn't mean the indices are going to see significant downside.

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

After a negative report on GW's epilepsy treatment, the analyst refused to explain the results with me, bringing more questions than answers about its conclusions.

GW Pharmaceuticals Could Fall Another 30% From Here

GW Pharmaceuticals Could Fall Another 30% From Here

Shares of the cannabinoid prescription medicine company look to be in a weak state.

CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That

CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That

Agency has the authority to carve out an exception to existing laws.

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

Let's see how the charts of GWPH are shaping up.

Zynerba Pharma Looks Like Bad Medicine for Investors

Zynerba Pharma Looks Like Bad Medicine for Investors

The charts make ZYNE look bearish and not particularly attractive, so avoid.

5 Cannabis ETFs to Fire Up Your Portfolio

5 Cannabis ETFs to Fire Up Your Portfolio

Two of them are brand new.

You Don't Have to Swing for the Fences With Every Investment in Small Caps

You Don't Have to Swing for the Fences With Every Investment in Small Caps

The way I do that is by using buy-write option strategies.

9 Speculative Plays for Investors Wanting Cannabis Exposure

9 Speculative Plays for Investors Wanting Cannabis Exposure

Five top marijuana stocks and four CBD plays in this speculative space.

2 Hemp Stocks for Investors Looking for Something Different

2 Hemp Stocks for Investors Looking for Something Different

You may want to check out GW Pharmaceuticals and Elixinol Global Limited.

Melius Research Launches Cannabis Industry Coverage

Melius Research Launches Cannabis Industry Coverage

In its first report on cannabis companies, Melius says prices are high.

GW Pharmaceuticals Is Ready to Rally More: How to Trade This Cannabis Stock

GW Pharmaceuticals Is Ready to Rally More: How to Trade This Cannabis Stock

My trading strategy for GWPH whether you are currently long or want to be.

Jim Cramer: My Best Stock Picks for Cannabis and China

Jim Cramer: My Best Stock Picks for Cannabis and China

And why I won't recommend any other stocks in these markets, right now.

Why Canada Rules as a Haven for Listing Cannabis Companies

Why Canada Rules as a Haven for Listing Cannabis Companies

The main reason most cannabis-related concerns head north to list their shares is banking.

Farm Bill's Hemp Legalization Is Poised to Boost These 2 Stocks

Farm Bill's Hemp Legalization Is Poised to Boost These 2 Stocks

Despite the current stock market, investors are still looking for ways to play the new legalization of hemp.

GW Pharmaceuticals Is Poised to Rally to New Highs, Risk Defined

GW Pharmaceuticals Is Poised to Rally to New Highs, Risk Defined

A potential great pipeline but let's check the charts.

Check Out These Stocks as Canada Is About to Be Smokin' Hot

Check Out These Stocks as Canada Is About to Be Smokin' Hot

On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

These stocks offer some diversification or unique features in the legal-weed space.

Down the Marijuana Rabbit Hole: 5 Companies to Consider

It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy.  As you go down the marijuana rabbit hole, ...

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.